Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 8/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 7/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 6/20 | 1.00 |
| ▸ | XDH | P47989 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | APP | P05067 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | BCHE | P06276 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | ACHE | P22303 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myricetin SCHEMBL19302 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Myricetin SCHEMBL3503992 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Myricetin SCHEMBL15609358 | 0.93 | MEN1 (0.89) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| SCHEMBL28432225 | 0.92 | MEN1 (0.85) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Myricetin SCHEMBL1064954 | 0.92 | MEN1 (0.92) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| Myricetin SCHEMBL1884289 | 0.91 | MEN1 (0.83) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| SCHEMBL29974792 | 0.91 | MEN1 (0.83) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| SCHEMBL21565056 | 0.91 | MEN1 (0.83) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| SCHEMBL7929171 | 0.90 | MEN1 (0.81) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 | |
| SCHEMBL15197351 | 0.89 | MEN1 (0.81) | MEN1KMT2ACYP1A2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11974982-B2 | Stimulus-responsive antioxidant crystals and method for their preparation | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-05-07 | — | — | US | claimed |
| CN-117589729-A | Method for detecting active oxygen scavenging effect of flavonoid compounds in living cells | 大理大学 | 2024-02-23 | — | — | CN | claimed |
| US-11896575-B2 | Transdermal formulation for delivery of hydrophobic compounds and process for the preparation thereof | DELIVRA INC. (CA) | 2024-02-13 | — | — | US | claimed |
| CN-113024502-B | Preparation method of 3,5,7,3',4',5' -hexahydroxy flavone | 陕西嘉禾生物科技股份有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-116096379-A | Composition exhibiting muscle loss-inhibiting or muscle generation-promoting effect through skin-derived exosomes | 伊艾斯健康护理有限公司 | 2023-05-09 | — | — | CN | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-112147249-B | UPC2-PDA-Q-Tof/MS detection method for 31 effective components in waxberry wine | 安徽瑞思威尔科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-114191391-A | Preparation method of myricetin-loaded nano-micelle for reducing ovariectomy-induced bone loss by inhibiting osteoclast formation | 蒋廷旺 | 2022-03-18 | — | — | CN | claimed |
| WO-2022018376-A2 | ECOBIOLOGICAL FORMULATION, COMPATIBLE WITH CELL LIFE, USABLE IN THE COSMETIC, DERMOPHARMACEUTICAL OR VETERINARY FIELDS | NAOS INSTITUTE OF LIFE SCIENCE (FR) | 2022-01-27 | — | — | WO | claimed |
| US-20260130861-A1 | THERAPEUTIC NANOPARTICLES WITH ANTIOXIDANT AND IRON-CHELATION ACTIVITY | UNIVERSITY OF OREGON (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260124225-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR USING SAME | KARNICK WILLIAM (US) | 2026-05-07 | — | — | US | disclosed |
| US-12611375-B2 | Injectable slurries and methods of manufacturing the same | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-12521367-B2 | Related formulations and methods related to eye irritation | LEBRUN LABS LLC (US) | 2026-01-13 | — | — | US | disclosed |
| CN-114191391-A | Preparation method of myricetin-loaded nano-micelle for reducing ovariectomy-induced bone loss by inhibiting osteoclast formation | 蒋廷旺 | 2022-03-18 | — | — | CN | disclosed |
| US-20220079874-A1 | INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220023327-A1 | MANGIFERIN-CONTAINING HERBAL COMPOSITIONS FOR IMPROVING SPORTS PERFORMANCE | NEKTIUM PHARMA, S.L. (ES) | 2022-01-27 | — | — | US | disclosed |
| WO-2022018376-A2 | ECOBIOLOGICAL FORMULATION, COMPATIBLE WITH CELL LIFE, USABLE IN THE COSMETIC, DERMOPHARMACEUTICAL OR VETERINARY FIELDS | NAOS INSTITUTE OF LIFE SCIENCE (FR) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022019187-A1 | EXTERNAL PREPARATION FOR COSMETIC AND COSMETIC | コスメディ製薬株式会社 | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124225-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR USING SAME | GCG, MC4R, GLP1R | MEN1 264/4885KMT2A 633/4885CYP1A2 1919/4885 |
| US-20260130861-A1 | THERAPEUTIC NANOPARTICLES WITH ANTIOXIDANT AND IRON-CHELATION ACTIVITY | GPX1, TXN2, TFRC | MEN1 3883/4885KMT2A 3514/4885CYP1A2 2342/4885 |
| US-11896575-B2 | Transdermal formulation for delivery of hydrophobic compounds and process for the preparation thereof | TTPA, TEAD2, CD69 | MEN1 2636/4885KMT2A 3570/4885CYP1A2 1304/4885 |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | GSTP1, GSTK1, GSTM1 | MEN1 4764/4885KMT2A 4095/4885CYP1A2 3629/4885 |
| US-12611375-B2 | Injectable slurries and methods of manufacturing the same | PYCARD, LIPG, NLRP3 | MEN1 2673/4885KMT2A 4119/4885CYP1A2 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.